Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.
Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, Chortis V, Cuthbertson DJ, Daousi C, Rajeev SP, Davis J, Cheer K, Drake W, Gunganah K, Grossman A, Gurnell M, Powlson AS, Karavitaki N, Huguet I, Kearney T, Mohit K, Meeran K, Hill N, Rees A, Lansdown AJ, Trainer PJ, Minder AE, Newell-Price J. Daniel E, et al. Among authors: rajeev sp. J Clin Endocrinol Metab. 2015 Nov;100(11):4146-54. doi: 10.1210/jc.2015-2616. Epub 2015 Sep 9. J Clin Endocrinol Metab. 2015. PMID: 26353009 Free PMC article.
Compensatory changes in energy balance during dapagliflozin treatment in type 2 diabetes mellitus: a randomised double-blind, placebo-controlled, cross-over trial (ENERGIZE)-study protocol.
Rajeev SP, Sprung VS, Roberts C, Harrold JA, Halford JC, Stancak A, Boyland EJ, Kemp GJ, Cuthbertson DJ, Wilding JP. Rajeev SP, et al. BMJ Open. 2017 Jan 27;7(1):e013539. doi: 10.1136/bmjopen-2016-013539. BMJ Open. 2017. PMID: 28132008 Free PMC article. Clinical Trial.
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, cross-over trial (ENERGIZE).
Rajeev SP, Roberts CA, Brown E, Sprung VS, Harrold JA, Halford JCG, Stancak A, Boyland EJ, Kemp GJ, Perry J, Howarth E, Jackson R, Wiemken A, Schwab R, Cuthbertson DJ, Wilding JPH. Rajeev SP, et al. Diabetes Obes Metab. 2023 Dec;25(12):3621-3631. doi: 10.1111/dom.15257. Epub 2023 Sep 5. Diabetes Obes Metab. 2023. PMID: 37667658 Clinical Trial.
Clinical Characteristics of COVID-19 Patients in a Regional Population With Diabetes Mellitus: The ACCREDIT Study.
Llanera DK, Wilmington R, Shoo H, Lisboa P, Jarman I, Wong S, Nizza J, Sharma D, Kalathil D, Rajeev S, Williams S, Yadav R, Qureshi Z, Narayanan RP, Furlong N, Westall S, Nair S. Llanera DK, et al. Front Endocrinol (Lausanne). 2022 Jan 13;12:777130. doi: 10.3389/fendo.2021.777130. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35095757 Free PMC article.
GLP-1 as a target for therapeutic intervention.
Rajeev SP, Wilding J. Rajeev SP, et al. Curr Opin Pharmacol. 2016 Dec;31:44-49. doi: 10.1016/j.coph.2016.08.005. Epub 2016 Sep 2. Curr Opin Pharmacol. 2016. PMID: 27591964 Review.
17 results